# ChipScreen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chipscreen

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.chipscreen.com
- Total disclosed funding: $25M
- Latest round: Series E (May 29, 2015)
- Investors on record: 11

## About

ChipScreen, founded in 2001 and based in Shenzhen, China, is a biotech company that specializes in the research & development of small molecule pharmaceuticals. The company's founder, Chairman and Managing Director, Xianping Lu, has a PhD from Peking Union Medical College and was formerly the Director of R&D at Galderma S.A.'s North American R&D Center. The company has applied for more than 680 invention patents and has been authorized more than 200. The company was listed on the IPO in 2019.

The company’s main business is the research and development of small molecule drugs. The company’s self - developed products include Chidamide, Chiglitazar, and Cirotinib. Its products are used in the fields of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and antiviral treatment.

The company generates revenue by providing innovative small molecule drugs.

## Funding rounds

- Series E, May 29, 2015 — Cowin Capital, Shenzhen Capital Real Estate Fund
- Series D, Sep 1, 2014, $16M — Detong Capital, Efung Capital, CCB Private Equity Investment Management
- Series C, Jan 20, 2013, $1.6M — Richland Equities
- Series B, Nov 1, 2009, $0.7M — Lilly Asia Ventures
- Series A, Mar 1, 2001, $6M — Beijing Venture Capital, TEDA Venture Capital, Vertex Ventures China
- Angel, Jan 1, 2000, $0.6M — Hidea Investment

## Investors

- Hidea Investment (https://capitalatlas.ai/funds/hidea-investment) — Angel
- Beijing Venture Capital (https://capitalatlas.ai/funds/beijing-venture-capital) — Series A
- TEDA Venture Capital (https://capitalatlas.ai/funds/teda-venture-capital) — Series A
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Richland Equities (https://capitalatlas.ai/funds/richland-equities) — Series C
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series D
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series D
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series D
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series E
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series E